SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
dc.contributor.author | Efe, Cumali | |
dc.contributor.author | Tascilar, Koray | |
dc.contributor.author | Gerussi, Alessio | |
dc.contributor.author | Bolis, Francesca | |
dc.contributor.author | Lammert, Craig | |
dc.contributor.author | Ebik, Berat | |
dc.contributor.author | Stattermayer, Albert Friedrich | |
dc.contributor.author | Cengiz, Mustafa | |
dc.contributor.author | Gokce, Dilara Turan | |
dc.contributor.author | Cristoferi, Laura | |
dc.contributor.author | Peralta, Mirta | |
dc.contributor.author | Massoumi, Hatef | |
dc.contributor.author | Montes, Pedro | |
dc.contributor.author | Cerda, Eira | |
dc.contributor.author | Rigamonti, Cristina | |
dc.contributor.author | Yapali, Suna | |
dc.contributor.author | Adali, Gupse | |
dc.contributor.author | Caliskan, Ali Riza | |
dc.contributor.author | Balaban, Yasemin | |
dc.contributor.author | Eren, Fatih | |
dc.contributor.author | Eskazan, Tugce | |
dc.contributor.author | Barutcu, Sezgin | |
dc.contributor.author | Lytvyak, Ellina | |
dc.contributor.author | Zazueta, Godolfino Miranda | |
dc.contributor.author | Kayhan, Meral Akdogan | |
dc.contributor.author | Heurgue-Berlot, Alexandra | |
dc.contributor.author | De Martin, Eleonora | |
dc.contributor.author | Yavuz, Ahmet | |
dc.contributor.author | Biyik, Murat | |
dc.contributor.author | Narro, Graciela Castro | |
dc.contributor.author | Duman, Serkan | |
dc.contributor.author | Hernandez, Nelia | |
dc.contributor.author | Gatselis, Nikolaos K. | |
dc.contributor.author | Aguirre, Jonathan | |
dc.contributor.author | Idilman, Ramazan | |
dc.contributor.author | Silva, Marcelo | |
dc.contributor.author | Mendizabal, Manuel | |
dc.contributor.author | Atay, Kadri | |
dc.contributor.author | Guzelbulut, Fatih | |
dc.contributor.author | Dhanasekaran, Renumathy | |
dc.contributor.author | Montano-Loza, Aldo J. | |
dc.contributor.author | Dalekos, George N. | |
dc.contributor.author | Ridruejo, Ezequiel | |
dc.contributor.author | Invernizzi, Pietro | |
dc.contributor.author | Wahlin, Staffan | |
dc.date.accessioned | 2023-02-21T12:42:56Z | |
dc.date.available | 2023-02-21T12:42:56Z | |
dc.date.issued | 2022-01-01 | |
dc.description.abstract | Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81\%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4\% vs. 14.2\%), need for any supplemental oxygen (29.5\% vs. 9\%) and mortality (7\% vs. 0.6\%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio {[}aOR] 0.18, 95\% confidence interval {[}CI], 0.10-0.31). Overall, vaccination against SARSCoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95\% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH. | |
dc.description.issue | OCT | |
dc.description.volume | 132 | |
dc.identifier.doi | 10.1016/j.jaut.2022.102906 | |
dc.identifier.uri | https://hdl.handle.net/11443/2861 | |
dc.identifier.uri | http://dx.doi.org/10.1016/j.jaut.2022.102906 | |
dc.identifier.wos | WOS:000911713800005 | |
dc.publisher | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | |
dc.relation.ispartof | JOURNAL OF AUTOIMMUNITY | |
dc.subject | Liver failure | |
dc.subject | Breakthrough infection | |
dc.subject | Immunosuppression | |
dc.subject | Vaccine | |
dc.subject | Autoimmunity | |
dc.title | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1